Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

Yekeduz, EmreErturk, IsmailTural, DenizKaradurmus, NuriKarakaya, SerdarHizal, MutluArslan, Cagatay2024-06-122024-06-1220210732-183X1527-7755https://doi.org/10.1200/JCO.2021.39.6_suppl.321https://hdl.handle.net/20.500.14551/25944ASCO Genitourinary Cancers Symposium (GU ASCO) -- FEB 11-13, 2021 -- ELECTR NETWORK[Abstract Not Available]en10.1200/JCO.2021.39.6_suppl.321info:eu-repo/semantics/closedAccess[No Keywords]Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.Conference Object396Q1WOS:000636801500336